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Protein productiona b s t r a c t
Protein aggregation is a widespread phenomenon that stems from the establishment of non-native inter-
molecular contacts resulting in protein precipitation. Despite its deleterious impact on fitness, protein
aggregation is a generic property of polypeptide chains, indissociable from protein structure and func-
tion. Protein aggregation is behind the onset of neurodegenerative disorders and one of the serious obsta-
cles in the production of protein-based therapeutics. The development of computational tools opened a
new avenue to rationalize this phenomenon, enabling prediction of the aggregation propensity of individ-
ual proteins as well as proteome-wide analysis. These studies spotted aggregation as a major force driv-
ing protein evolution. Actual algorithms work on both protein sequences and structures, some of them
accounting also for conformational fluctuations around the native state and the protein microenviron-
ment. This toolbox allows to delineate conformation-specific routines to assist in the identification of
aggregation-prone regions and to guide the optimization of more soluble and stable biotherapeutics.
Here we review how the advent of predictive tools has change the way we think and address protein
aggregation.
 2020 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
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Proteins are the ultimate and essential cellular players in almost
all biological processes, coordinating different functions inherent
to life through the establishment of molecular networks in the
overcrowded cellular milieu [1]. This activity is mediated by speci-
fic inter-molecular interactions that finely regulate protein home-
ostasis and functioning [2]. In contrast, non-native protein–protein
interactions can prompt aberrant oligomerization and ultimately
protein aggregation, a process associated with the onset of a wide
range of human disorders -including Alzheimer’s, Parkinson’s dis-
eases and type II diabetes [3–4]. Such detrimental property is not
restrained to disease-related proteins but widespread and is con-
sidered a generic trait of polypeptides chains. Indeed, protein
aggregation constitutes a significant bottleneck in the production
of protein-based therapeutics, compromising their recombinant
expression, downstream processing, and biosafety, precluding the
marketing of otherwise promising biotherapeutics [5–6]. It is
therefore essential to elucidate the molecular determinants of pro-
tein aggregation, its biological connection with native functions,
and its role in shaping protein evolution since such knowledge
would translate into advances in biomedicine and biotechnology.
Proteins aggregate in variety of physicochemical diverse
supramolecular assemblies ranging from highly ordered cross-b
amyloid fibrils, formed by a repetitive array of monomers disposed
orthogonally to the fibril axis, to less ordered amorphous deposits
[7]. In between, an array of oligomeric and protofibrillar structures
display intermediate structural properties. The same polypeptide
chain can form fibrillar or amorphous assemblies depending on
its microenvironment [7–10]. Indeed, the molecular determinants
driving the formation of fibrils in amyloidosis and less ordered
aggregates during biologics production overlap significantly, mak-
ing difficult to predict if the assembly of a given protein in a given
condition will lead to one or other kind structure, or something in
between [7]. Additionally, there exist a number of proteins, known
as functional amyloids, that exploit the amyloid fold to perform
their physiological activities [4,11–12]. For instance, functional
amyloids are involved in curli-mediated biofilm formation in
E. coli [13], hypersensitive response activation in plants [14], mel-
anin polymerization in mammalian cells [15], and hormone stor-
age in humans [16]. Functional and non-functional aggregation
have evolved under selective pressures of different signs, which
favored and disfavored them, respectively [17–19]. This review
focus on undesired aberrant protein aggregation and how it can
be predicted and modulated.
Great efforts have been devoted to the analysis and characteri-
zation of specific aggregation-prone proteins, which crystallized
into a robust theoretical comprehension of the protein aggregation
phenomenon [20–21]. Yet, it remains challenging to translate
these learned rules to previously uncharacterized proteins, and
their study requires the dedicated and manual inspection of their
sequences and folds.
Fortunately, in silico approaches have evolved hand-in-hand
with the development of the field, and have become powerful plat-
forms to systematically project our empirical and theoretical
knowledge into unstudied protein sequences or structures [22–
23]. To date, more than 30 algorithms have been implemented to
deal with protein aggregation, allowing to identify aggregation
determinants, predict the effect of disease-related mutations, and
assist in the redesign of protein solubility [23–24]. Each of these
programs relies on different principles and assumptions and face
the aggregation conundrum from diverse perspectives. This diver-
sity provides us with a versatile toolbox to orthogonally combine
the outputs of conceptually different algorithms and adapt the pre-
dictive strategy to the intended purpose. Noteworthy, these pre-
dictive tools allow for the fast evaluation of extensive collectionsof protein variants or even complete proteomes, which has con-
tributed substantially to illuminate the connection between pro-
tein function and aggregation while uncovering aberrant
aggregation as an important constrain of protein evolution [25–
27].
In this article, we review some of the most critical biocomputa-
tional advances that have contributed to our present understand-
ing of the constraints shaping non-functional protein aggregation
in living organisms, helping to provide biological context for the
protein aggregation phenomenon. We define a framework for pre-
dicting protein aggregation, taking into account that function and
aggregation are often two sides of the same coin. We intend to pro-
vide a comprehensive compendium of strategies that can be
adapted to any specific protein of interest. We end up illustrating
the potential of state-of-the-art algorithms to assist in the design
and control of the solubility of proteins of biotechnological
interest.2. Proteome-wide analysis: A biological framework for protein
aggregation
The implementation of predictive tools with the ability to sys-
tematically analyze extensive collections of proteins has allowed
extending the analysis of aggregation to complete proteomes,
resulting in a deeper understanding of the molecular determinants
that govern protein aggregation while revealing crosstalk between
protein evolution and aggregation [28–30]. Different computa-
tional proteome-wide analyses converged in the identification of
aggregation-prone regions (APRs) similar to those identified in
disease-linked proteins across all kingdoms of life [31]. The pres-
ence of these sequence stretches is not anecdotic since an average
of one APR per protein was detected, independently of the consid-
ered proteome. APRs have been identified in proteins with differ-
ent conformational properties: intrinsically disordered, globular,
transmembrane, or oligomeric proteins. Overall, these computa-
tional studies suggest that APRs are ubiquitously present in nature
and are an intrinsic trait of proteins, despite being potentially
harmful. Of note, the predicted aggregation propensity of pro-
teomes substantially decreases with increasing complexity and
longevity of organisms, which seems to point to an evolutionary
pressure acting against protein aggregation [26,31]. Yet, the aggre-
gation phenomena persist, indicating that negative selection can-
not wholly abrogate it.2.1. Defining the interplay between functional and aberrant contacts.
Cells have evolved a complex network of quality control mech-
anisms to mitigate protein aggregation in order to maintain pro-
tein homeostasis. Such strategies consume significant cellular
energy [32]. Thus, the omnipresence of APRs in proteins does not
only endorse themwith the risk of sporadic aggregation but consti-
tutively drain a substantial amount of cellular resources. It is then
shocking that despite millions of years of evolution sharpening
protein sequences and structures, protein aggregation has not been
purged out from polypeptides. This resilience against negative nat-
ural selection has been interpreted as an indication of APRs being
essential to develop certain biological functions [33]. Multiple
experimental and computational studies converge to demonstrate
that the physicochemical determinants of protein aggregation sub-
stantially overlap with those responsible for the establishment of
native intra- and intermolecular contacts (i.e., substrate binding,
protein folding, or protein–protein interactions) [34–37]. This
observation can be easily understood by considering that regions
responsible for native contacts are usually hydrophobic and prone
to establishing hydrogen-bonded networks, two features that also
Fig. 1. Innate competition between functional interactions and protein non-functional aggregation. Several factors contribute to balancing this subtle equilibrium.
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aggregation. In globular proteins, the evolutionary suppression of
APRs is often restrained by the need for a densely packed
hydrophobic core to maintain their native fold [38–39]. The inter-
face between protein sub-units or protein complexes is also
enriched in hydrophobic residues that stabilize the quaternary
structure. Accordingly, protein folding, stability, and aggregation
are in a close interplay in globular proteins, being governed by
the same molecular features, but differently weighted [35,40].
Computational algorithms have contributed substantially to
clarify the function-aggregation interplay by assisting the experi-
mental characterization of some archetypical protein examples.
In this way, in the human Josephin domain, the residues with
higher contributions to its predicted aggregation propensity are
also fundamental for the ubiquitin-binding activity of the protein
[41]. Solubilizing mutations affecting those residues lead to a con-
comitant loss of activity. Likewise, the aggregation of the human
SUMO protein repertoire (SUMO1, SUMO2, and SUMO3) is directed
by specific regions that overlap with SUMO functional interfaces
[42]. All in all, protein regions accounting for the protein function-
ality might -under some circumstances- lead to aberrant contacts
and eventually to protein aggregation, depicting an intrinsic com-
petition between these two opposed reactions (Fig. 1).
2.2. Computational identification of the evolutive strategies
constraining protein aggregation
As discussed, almost every polypeptide is endorsed with an
inherent risk to suffer aggregation and, potentially compromise
cellular fitness. However, it is also true that proteins remain sol-
uble and functional in their natural contexts, and only under cer-
tain conditions (i.e., mutations, gene duplications, or aging), a
reduced set of proteins are found accumulated into insoluble
deposits in vivo [4,43]. Thus, it becomes clear that if APRs cannot
be skipped from protein sequences and structures, alternative evo-
lutionary strategies must have emerged to cope with their pres-
ence. Chaperones, co-chaperones, and degradation systems
constitute the first line of defense against aggregation. In addition
to this protein quality control machinery, large-scale computa-tional analysis identified other submerged regulation mechanisms
to counterbalance the unavoidable aggregation propensity of pro-
teins [30–31]. These strategies are adapted to the protein size,
half-life, in-cell relative concentration, sub-cellular location, and
translation rate.
Correlations between protein size and foldability report that
longer and multi-domain proteins usually fold slower than short
and single-domain polypeptides [44]. Hypothetically, if all pro-
teins harvest equivalent aggregation loads, longer sequences
would be more susceptible to aggregate as a result of more pro-
longed exposure of their APRs to solvent [31,45]. Computational
studies of bacterial proteomes revealed that single-domain pro-
teins (below 20 kDa) could accommodate a higher aggregation
load; the average aggregation propensity decreases with increas-
ing protein lengths [26]. Complementarily, the principal bacterial
chaperones GroEL, and DnaK bind preferentially to substrates
above the 20 kDa limit [46]. The same trend has been reported
for the human proteome, highlighting the conservation of a con-
trol mechanism aimed to cope with the theoretical increased risk
of aggregation associated with longer proteins [25]. Aggregation
propensity is also connected to protein turnover; De Baets and
co-workers analyzed 611 protein sequences and their lifetimes
with the aggregation predictor TANGO [47]. They show that
short-living proteins can accommodate a higher aggregation load
since their time window to misfold and aggregate is smaller than
that of proteins with higher lifetimes.
The analysis of the aggregation propensity of proteins in differ-
ent cellular compartments has documented a connection between
protein location and aggregation in yeast, bacterial, and human
proteomes [25–26,48]. Tartaglia and co-workers proposed that
protein solubility correlates with the volume of the cellular com-
partment they populate: in smaller subcellular locations proteins
display lower aggregation tendencies, likely a strategy to prevent
abnormal interactions in more crowded environments [49].
Sequences of proteins that undergo secretory pathways or residing
in the periplasm are, on the average, more soluble, probably
because they are more exposed to extracellular stresses and have
little access to protective chaperones, which are significantly
depleted in those environments [25–26].
1406 J. Santos et al. / Computational and Structural Biotechnology Journal 18 (2020) 1403–1413Elevated protein expression has been traditionally linked with
the formation of aberrant protein deposits, either in conforma-
tional disorders or during recombinant expression [50–52].
According to the law of mass action, the probability of establishing
non-functional interactions scales with the protein concentration
[53]. Certainly, in contrast to protein folding, aggregation is a sec-
ond or higher-order reaction, being strongly dependent on protein
abundance. Several proteomics analyses revealed that there exists
an anti-correlation between gene-expression and/or protein abun-
dance and predicted aggregation propensity in bacteria, nema-
todes, and humans [49,54–56]. In essence, protein abundance in
the cell is tightly regulated to attain optimal levels, sufficient for
proteins to remain soluble and functional, but not more than that.
Vendruscolo and co-workers have extended this hypothesis by
proposing that ‘‘supersaturated” proteins -a subset of proteins liv-
ing above their solubility limit- conform a metastable subpro-
teome inherently exposed to aggregation [57–59]. They suggest
that after the primary aggregation of the disease-causing amyloid
proteins -i.e., Ab42 or a-synuclein-, ‘‘supersaturated” proteins are
collaterally more exposed to aggregation, expanding the dysfunc-
tion to other unrelated biological pathways and prompting a gen-
eral collapse of cellular functions.
Computational analyses also revealed a link between protein
aggregation and function [26,48,60]. Chen and co-workers demon-
strated that essential proteins from three eukaryotic organisms -
yeast, fly, and nematode- are the subject of a higher evolutionary
pressure against protein deposition [60]. Similarly, in bacteria,
operons that encode essential proteins or functions display lower
aggregation loads [26]. It is not surprising that proteins in the same
operon display similar aggregation propensities since they share
common gene-expression regulation and thus abundance, all
working in related functions.
The above-described relationships have been established by
analyzing aggregation over protein sequences, without taking into
account the modulation of these properties by the structural con-
text in the folded states in which proteins spend the majority of
their lifetime. Performing an equivalent structure-based proteomic
analysis is not trivial since the available protein structures for aFig. 2. Computational strategies to predict protein aggregation. In each folding state
performing predictive strategy in each particular case. Aggregation-prone residues ar
Aggregation-Prone Regions and STructural Aggregation-prone Regions, respectively. PDB
interpretation of the references to colour in this figure legend, the reader is referred togiven proteome are limited, and their analysis requires significant
computation time. Despite these limitations, in a recent work, we
analyzed a fraction of the structurally characterized Escherichia coli
proteome to explore whether, in addition to sequence properties,
structural aggregation might also influence the evolution of bacte-
rial proteins [61]. Our analysis revealed that the aggregation fea-
tures of protein surfaces and interfaces in folded states are
constrained according to the protein abundance, length, essential-
ity, subcellular location, and function. This observation indicates
that protein structures would have also evolved to minimize the
risk of aggregation in their natural environments.3. Prediction of protein aggregation from different native
conformations
The previous section illustrates how protein aggregation cannot
be understood without considering the folding, functional purpose,
and cellular environment of a protein. In each conformational
state, the risk of aggregation stems from different sources; globular
proteins, IDPs, and oligomeric proteins pose different challenges
that need to be addressed with dedicated tools. Therefore, in order
to anticipate protein aggregation successfully, we need to adapt
our computational scheme to the particular properties of the pro-
tein under study. Such a task can be difficult for untrained users
since an in-depth knowledge of the available computational tools
is needed. In this section, we apply the insights provided by
proteome-wide analysis to classify and review a state-of-the-art
collection of predictive tools. The aim is to establish a systematic
framework for evaluating protein aggregation that can be adapted
to the intended predictive purpose (Fig. 2).3.1. Sequence-based predictors
The first generation of computational algorithms designed to
predict protein aggregation is based on the identification of linear
APRs across the polypeptide sequence. The conceptual pillars of
these algorithms are the theoretical and experimental studies that, aggregation is driven by different molecular determinants, delimiting the best-
e colored in red and solubilizing amino acids in blue. APR and STAP designate
structures correspond to monomeric and tetrameric transthyretin (PDB: 1F41). (For
the web version of this article.)
Table 1
Sequence based-prediction methods, according to the rationale behind their analysis. *Registration prior to analysis is required.
Method* Underlying rationale Webserver, software or equation
Phenomenological methods
AGGRESCAN [63,64] Prediction is assayed against an aggregation propensity scale for the 20
proteinogenic amino acids derived from in vivo experiments.
http://bioinf.uab.es/aggrescan/
Zyggregator [65] Prediction of a 21-residue sliding window from an equation
accounting for hydrophobicity, secondary structure propensity, and
net charge built upon changing aggregation rate on mutations.It also
considers the presence of gatekeeper residues or hydrophobic patches
http://www-mvsoftware.ch.cam.ac.uk/index.php/login*
Theoretical methods
TANGO [7,117] Evaluation of the population of random coil, native conformation or
aggregated species from empirically and statistically derived
conformational amino acidic preferences, along with physico-chemical
variables.
http://tango.crg.es/ *
PASTA 2.0 [66,118] Energetic function derived from high-resolution protein structures,
which considers interaction potential and H-bond formation between
all non-consecutive residues for parallel and anti-parallel b-pairing.
http://protein.bio.unipd.it/pasta2/
FoldAmyloid [67] A protein structure derived scale; from the notion that hydrophobic
stretches exhibit higher ‘‘packing density” and H-bonding propensity.
http://bioinfo.protres.ru/fold-amyloid/
WALTZ [68] Application of a position specific matrix derived from a large group of
hexapeptides, for predicting amyloid-like formation.
https://waltz.switchlab.org/
Pafig [119] Analysis of six-residue sliding window for a scale derived from
machine supervised learning over 531 physicochemical properties,
which led to best discrimination using 41 of them.
Code can be downloaded from their web page http://
www.mobioinfor.cn/pafig/ (Requires MS Windows)
Betascan [120] Evaluation of b-strand pairing propensity, obtained from probabilities
of residues to be H-bonded in amphiphilic b-sheets.
http://cb.csail.mit.edu/cb/betascan/ hosts the web server and
allows download of the Perl scipt.
GAP [121] Discriminates amyloid-like or b-amorphous hexapeptides from
position-specific pairing frequencies.
https://www.iitm.ac.in/bioinfo/GAP/
3D Profile [122] Energetic impact on the spatial accommodation to the backbone of the
fibril forming Sup35 hexapeptide is assessed.
http://services.mbi.ucla.edu/zipperdb/ *
Machine learning methods
APPNN [71] Machine learning approach based on the analysis of seven
physicochemical and biochemical features such as b-sheet frequency,
hydrophobic moment, helix termination parameters or isoelectric
point.
http://cran.r-project.org/web/packages/appnn/index.html
NetCSSP [72] Analysis of contact-dependent secondary structure prediction to
identify hidden b-propensities.
http://cssp2.sookmyung.ac.kr/
FiSH Amyloid [73] Classification of amyloidogenic stretches based on co-ocurrence




AmylPred2 [74] Generates consensus predictions over 11 algorithms but allows user-
customized predictions as some methodologies can have a certain
degree of redundancy, thus biasing the consensus prediction.
http://aias.biol.uoa.gr/AMYLPRED2/ *
MetAmyl [75] Score is obtained applying a linear combination of four predictors’
(which showed lower redundancy) outcome, weighting the individual
contribution of each method.
http://metamyl.genouest.org
* This list intends to be illustrative and not to provide an extensive enumeration and description of all available methods. Programs in this list are not necessarily more
accurate than those absent.
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aggregation. To date, more than 20 sequential algorithms have
been developed [23,62]. Their design exploits the evidence that
protein aggregation is driven by short and well-defined sequential
stretches -referred to as APRs- characterized by a high hydropho-
bicity, low net charge, and a remarkable preference to adopt b-
sheet secondary structure [23]. However, each algorithm relies
on different interpretations and weighting of the essential features
driving aggregation, which allows the orthogonal combination of
conceptually different algorithms to reduce method-specific
biases. These algorithms can be divided into four subclasses
according to their underlying principles, further described in
Table 1. Briefly, the first class of algorithms, known as phe-
nomenological, employs experimental data to define the determi-
nants of aggregation and provide empiric aggregation scales. They
include software such as AGGRESCAN, and Zyggregator, both based
on the rationalization of experimentally determined factors influ-
encing protein aggregation [63–65]. The second class of computa-
tional approaches relies on the theoretical assessment of sequence
properties known to be associated with aggregation. TANGO,
PASTA 2.0, FoldAmyloid, Waltz and Amyloid Mutants belong to thissecond class, and they evaluate the tendency of a sequence to
adopt a defined b-enriched conformation, the packing density of
proteins, the composition and patterning of their residues or the
suitability to adopt the topologically restricted conformations that
characterize amyloid-like states [66–69]. A growing number of
machine learning methods are being developed. They exploit
the potential of neural networks to identify sequential features
highly correlated with aggregation [70]. Machine learning
approaches attain performances comparable -or even higher- to
traditional predictors. APPNN, netCSSP or FISH Amyloid are some
examples of this kind of algorithms [71–73]. Finally, a last group
of software is the one based on the combination and weighting
of the outputs of other predictors (either phenomenological or the-
oretical) into one single output. These consensus predictors
assemble the different concepts behind each predictor to increase
robustness while reducing method-specific biases. AMYLPRED 2
and MetAmyl exemplify this kind of software [74–75].
The aforementioned programs are just our lab selection among
the more than 20 available algorithms that have demonstrated
their efficacy in the study of disease-related proteins, allowing to
discretize the experimentally relevant sequence stretches driving
1408 J. Santos et al. / Computational and Structural Biotechnology Journal 18 (2020) 1403–1413their aggregation [4,23,29,31]. They are these tools that allowed for
most of the above aforementioned proteome-wide analysis [31].
However, they do not evaluate the modulation of sequential aggre-
gation determinants imposed by the three-dimensional conforma-
tion of the protein. This drawback defines the particular scenarios
in which their predictions are particularly accurate: (i) Intrinsically
disordered proteins; these proteins lack a defined three-
dimensional structure and fluctuate between multiple transients
unfolded or partially folded conformations. During these dynamic
fluctuations, APRs are accessible to the solvent, without significant
structural protection. (ii) After being synthesized in the ribosome,
proteins depart from an extended conformation that transits
towards the folded state. During this process, APRs are also
exposed to the solvent. This situation is of particular relevance dur-
ing protein overexpression, where the transient concentration of
unfolded polypeptide chains increases dramatically (iii) Dynamic
fluctuations or destabilization of protein structures may result in
the partial unfolding, exposing previously hidden APRs.
Therefore, the straightest application of sequence-based algo-
rithms is the prediction of IDPs aggregation. IDPs are particularly
depleted in APRs since the compositional bias of disordered pro-
teins inherently protects them from aggregation. In essence, they
contain a significant proportion of protective residues (Asp, Arg,
Glu, Gly, Lys, and Pro), so-called gatekeepers, that are difficult to
accommodate in a b-sheet aggregated state [7,76–78]. However,
IDPs are not entirely protected against aggregation, and this stems
from their innate biological functions. IDPs are generally involved
in multiple protein–protein interactions, acting as signal integra-
tors and master regulators of diverse biological processes [79].
Such activity entails the presence of short molecular recognition
motifs that must be at least transiently exposed to the solvent to
find their suitable binding partner. Those motifs retain an intrinsic
hydrophobicity, and under pathogenic conditions, they may act as
cryptic APRs, triggering aberrant interactions and finally, protein
aggregation. Accordingly, computationally identified APRs in IDPs
tend to overlap with interaction motifs; in a recent work, we have
computationally identified and characterized the aggregation of
one of such sequence stretches [80]. Ab42, a-synuclein or IAPP
are some examples of IDPs whose aggregation is associated with
human disorders [4,81]. In these proteins, different algorithms
consistently predict APRs that overlap with the regions identified
to drive the aggregation in vitro and lately to be part of the core
that sustains the respective amyloid fibrils structure [82–85].
3.2. Structure-based algorithms
Structure-based algorithms were born as a second generation of
software designed to translate the predictive potential of
sequence-based algorithms to globular proteins. In folded proteins,
the three-dimensional arrangement of the polypeptide chain sig-
nificantly reshapes the molecular determinants of aggregation,
weighting the contribution of linear APRs [86]. Sequence-based
algorithms are blinded to these effects, which usually result in
overprediction when they are used to forecast the aggregation
propensity of folded proteins. In this way, the architecture of glob-
ular proteins buries the hydrophobic residues inside the protein
core, blurring the exposition of linear APRs to solvent. Thus, once
a protein is folded into its compact tertiary structure, those APRs
do not contribute to protein aggregation, although sequence-
based algorithms would predict the contrary. Moreover, in a folded
protein, neighbor residues do not need to be consecutive in
sequence, and structural clustering of non-consecutive hydropho-
bic residues in the surface or interface of the protein might occur.
Those solvent-exposed hydrophobic patches, known as STructural
APRs (STAP), are usually crucial for the protein activity, as previ-ously discussed for the Josephin domain and the SUMO proteins.
This is also the case of antigen-recognition elements in antibodies
that exhibit a relatively high exposed hydrophobicity required for
target binding [87]. Of course, STAPs cannot be identified by linear
predictors.
Structure-based algorithms use three-dimensional protein
coordinates in order to evaluate the aggregation of proteins in their
native fold and overcome the limitations mentioned above. Herein,
we briefly describe the principles of four of the more popular
structure-based algorithms. Their applications to the redesign of
therapeutic proteins will be further reviewed in section 4.
SolubiS constitutes one of the most instinctive evolutions of a
linear predictor to evaluate the structural context [88]. SolubiS
identifies linear APRs -using the TANGO sequence-based
algorithm- and applies the FOLDX force field to evaluate their con-
tribution to global protein stability [89]. The result is an algorithm
able to analyze the structural context and the relative shielding of a
given APR and provide an estimation of the tendency of such APR
to be solvent-exposed and thus become aggregation competent.
SolubiS has successfully forecasted the behavior of model globular
proteins in vitro and is an excellent tool to evaluate the impact of
APR sequential variations in the solubility of the protein. Nonethe-
less, since SolubiS was build using a sequence-based predictor, this
software is still blinded to the emergence of STAPs. SAP (spatial
aggregation propensity) was the first algorithm designed with this
objective, being able to identify hydrophobic patches exposed to
solvent in globular proteins [90]. SAP uses a structurally corrected
hydrophobicity scale as a proxy for protein aggregation and con-
siders that the aggregation contribution of a given side chain is
modulated for the residues in the vicinity. Under that premise,
SAP defines a 5 Å radius sphere centered in the analyzed atom
and evaluates the spatial contribution of each nearby residue as
the product of the solvent-accessible area of the atoms within
the sphere. In this way, SAP analyzes the local hydrophobicity of
solvent-exposed residues regardless of their sequence positions.
The Developability Index algorithm (DI) is an adaptation of SAP
to predict the aggregation of monoclonal antibodies (mAbs) based
on their structure in a faster and more accurate way [91]. DI
includes the effect of electrostatic interactions, which have an
essential role in solubility, counterbalancing the contribution of
hydrophobicity. Aggrescan3D (A3D) is another example of
structure-based algorithms, implementing the sequence-based
AGGRESCAN aggregation scale to assess the aggregation of protein
structures [92–93]. A3D is conceptually similar to SAP, but it intro-
duces an experimentally derived aggregation scale instead of using
hydrophobicity. A3D calculates the aggregation propensity of each
residue by computing its intrinsic aggregation propensity, which is
also corrected by its solvent-exposure and properties of the side
chains in the vicinity. The main particularity of A3D, when com-
pared with other structure-based algorithms, is its capacity to
assess the impact of dynamic structural fluctuations of protein
structures and its effect on the exposition of APRs. The A3D ‘‘dy-
namic mode” uses the CABS-flex force field -based on high resolu-
tion coarse-grained molecular dynamics simulations- to reproduce
the dynamism and plasticity of protein structures in their native
states [94–95]. For each particular conformer generated by CABS-
flex, A3D computes its structural aggregation propensity. In this
way, A3D allows the identification of dynamic aggregation-prone
regions that are otherwise protected in the static PDB deposited
structure [96]. Another structure-based approach has been devel-
oped by Sormanni and coworkers [97] The CamSol method applies
the physicochemical principles implemented in the sequence-
based predictor Zyggregator and performs structural corrections
similar to those of SAP or A3D to compute the solubility of native
protein structures [65].
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The computational analysis of native oligomeric assemblies
revealed that, as a general trend, protein–protein interfaces display
higher aggregation propensities than the solvent-exposed surfaces
of globular proteins [37]. Indeed, a remarkable overlap between
interaction surfaces and APRs has been identified in oligomeric pro-
teins associated with conformational disorders, indicating that the
functional interaction of themonomeric subunits is associated with
an intrinsic risk of aggregation. This exposed hydrophobicity in
monomeric subunits becomes masked once they are incorporated
in the quaternary structure. Accordingly, in disease-linked oligo-
meric proteins, pathological mutations usually impact the complex
stability, favoring the dissociation of the aggregation-prone mono-
meric constituents. This is the case of transthyretin and SOD1, for
which the disentangle of the quaternary structure is the rate-
limiting step in the downhill polymerization process that drives
their aggregation; once the tetramer is destabilized, aggregation
becomes highly favorable [98–99]. Besides, upon disassembly, the
monomeric subunits become ‘‘supersaturated,” in comparison with
the respective multimeric protein, which exacerbates the probabil-
ity of spurious intermolecular contacts. For these proteins, in addi-
tion to STAP detection and scoring, accurate predictions of
aggregation should also evaluate the thermodynamic stability of
the assembled protein and how amino acid substitutions impact
both factors. In this context, the FOLDX force field is useful for the
identification of both stabilizing and destabilizing mutations asso-
ciated with the aggregation of oligomeric proteins [89].4. Aggregation in the biotechnological production of protein-
based therapeutics.
The use of recombinant proteins for therapeutic applications
offers a compelling alternative to small molecules. Proteins are
capable of performing highly specific and intricate functions,
which is impossible for small molecule drugs. The high specificity
of proteins also results in less drug toxicity through interference
with normal body processes. Aggregation is a significant concern
in the production of protein therapeutics, and it may jeopardize
the viability of the complete biotechnological process [5,100–
101]. First, because aggregation reduces production yields, but
most importantly because aggregates have the potential to trigger
immunogenic responses upon administration, threatening
patients’ health [102–103]. Consequently, biotech companies allo-
cate extensive funding and resources to mitigate protein aggrega-
tion in their production pipelines; often by undertaking expensive
trial/error screenings of conditions that may or may not result in a
significant improvement. On top of that, aggregation can occur at
every step of the process, from expression and purification to for-
mulation and storage [104]. These aggregation-related issues stem
from a simple principle: proteins are not selected to remain soluble
out of their evolutionary context. In an external environment, the
natural competition between functional and aberrant contacts is
imbalanced by the absence of native binding partners, quality con-
trol systems, and deregulation of protein concentration, leading to
uncontrolled intracellular protein deposition. Indeed, because
protein-based drugs should be administered in most cases par-
enterally, protein concentration in the final formulation can exceed
200 mg/mL, being several orders of magnitude above their natural
abundances [105]. Besides, during industrial processes, polypep-
tides are exposed to unnatural stresses such as pH-changes, shear-
ing effects, or temperature fluctuations, impacting both their
solubility and stability.
In this framework, the computational prediction of protein
aggregation offers an avenue to work with pre-selected and well-characterized protein candidates producing more soluble, stable,
and long-lasting therapeutic proteins (Fig. 3). Several of the algo-
rithms cited in the previous section have been exploited to screen
for more soluble protein variants and/or introduce solubilizing
mutations. Human a-galactoside or Bacillus anthracis protective
antigen are examples of biotherapeutic proteins whose solubility
has been successfully redesigned by using SolubiS, reducing their
aggregation propensity while maintaining their functional activity
[106]. Such approximation has also been translated to the redesign
of mAbs, which currently represent the faster-growing class of bio-
therapeutic molecules. SolubiS has successfully ranked a set of
mAbs according to their aggregation, also being able to apply this
predictive potential to the redesigning of these complex macro-
molecules into more soluble variants [87]. As a dedicated tool for
antibody predictions, the DI algorithm also allows the screening
of the aggregation propensity of mAbs in the early phases of drug
discovery; thus, the development of pre-screened candidates can
be prioritized attending to their solubility.
Finally, A3D offers a user-friendly platform for the design of
protein solubility by integrating structural aggregation predictions
with stability prediction since, eventually, solubilizing mutations
at the protein surfaces may have destabilizing effects on the native
structure, even if the involved residues are fully exposed to solvent
[107]. Towards the optimization of such a feature, we have
recently updated A3D with an ‘‘Automated mutations” mode that
automatically ranks solubilizing mutations in the protein surfaces
according to their effect on aggregation and stability. This new
module was tested for the redesign of a human variable heavy
chain of the human antibody germline, allowing the identification
of solubilizing mutations that do not perturb the stability of the
antibody fragment. This routine will significantly reduce the time
dedicated to the visual inspection of protein structures and manual
selection of mutations [107]. Of note, A3D users can pre-exclude
the complementarity-determining regions (CDRs) from the auto-
mated round of analysis. This is important because several previ-
ous phage display initiatives aimed to increase Abs solubility
have resulted in variants in which the mutations cluster in or close
to the hydrophobic CDRs, with the subsequent risk of hampering
antigen-recognition [108]. The automated A3D selected mutations
lay sequentially and structurally far from the CDRs, yet they signif-
icantly increased the solubility of the Ab of interest when this was
incubated under harsh conditions. The main advantage of this
upgrade is that it permits its use to academic and industrial fellows
that did not have extensive training in protein redesign.5. Modulation of the environmental conditions on the
prediction of protein aggregation.
The vast majority of proteins reside and develop their functions
in highly complex and overcrowded cellular microenvironments
exposed to unpredictable stresses that may impact their solubility
[52,109]. However, in the absence of external stressors, cellular
conditions tend to remain relatively constant and the extrinsic fac-
tors impacting protein aggregation are not expected to change sig-
nificantly over time. Thus, even if the prediction of aggregation
in vivo is far from being trivial, for the computational evaluation
of this property, it can be considered that we face a defined and
constant environment. In stark contrast, during industrial manu-
facturing, proteins are often exposed to very different conditions
that affect their physical stability [110]. For instance, more than
65% of antibodies and related constructs are formulated at
pH < 6.5 [5,111]. Yet, only a small set of in silico tools have been
designed to address the protein background, and many of them
only collaterally with barely parametrized functions. The
sequence-based predictors TANGO and Zyggregator can evaluate
Fig. 3. Comparison between a computationally guided pipeline for optimizing protein-based biotherapeutics and currently used strategies. The computational analysis of a
candidate pool and/or the reduction of their aggregation by introducing solubilizing mutations offers a powerful alternative to expensive and blinded trial/error approaches,
being cost-effective strategies to increase the success rate in the development of protein-based therapeutics.
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predicting the pH-dependent solubility of experimentally charac-
terized proteins is relatively low; mostly because they do not com-
pute the partial charge of the side chains [7,65,112–113]. The first
algorithm in which pH was implicitly considered is DI. DI can eval-
uate the net charge -accounting for partial ionization- of mAbs in a
pH-dependent way. In such a way, DI can evaluate if mAbs with
similar solubility in neutral conditions would have different solu-
bility in a particular step of the purification, thus extending the
pre-selection and optimization of candidates to a more realistic
level. One of the main disadvantages of this approach and other
related applications is that they only evaluate the effect of pH in
terms of its modulation over protein net charge. However, it is
well-known that the protonation/deprotonation of the ionizable
residues also has a significant effect in the hydrophobicity, as illus-
trated by their shifts in the partition coefficients upon changes on
the solution pH [114–115]. On that basis, we have recently built a
novel phenomenological model to predict the effect of pH on the
aggregation of IDPs considering both fluctuations in hydrophobic-
ity and global net charge [116]. Our algorithm calculates the pH-
dependent hydrophobicity along the sequence at a given pH and
computes the effect of the global protein net charge in order to
profile the pH-dependent solubility of a given protein. Such an
approach has demonstrated a higher predictive potential than
mere charge-dependent approaches stressing the importance of
including the changes in hydrophobicity in future predictiveendeavors. We expect that this model would inspire the imple-
mentation of novel structure-based algorithms, including this fea-
ture, to develop more robust and versatile software.6. Conclusions
The widespread nature of aggregation influences every aspect of
protein function and applications either in vivo or in vitro, from dis-
ease onset to the production of biotherapeutics. Accordingly, it
becomes fundamental to develop new tools to systematically
address protein aggregation issues in a fast and reliable way, with
the ultimate objective of transforming this arbitrary and unpre-
dictable process into an anticipatable variable. Nowadays, in silico
approximations are being progressively integrated into the routi-
nes of many laboratories, being cost-effective tools to assist and
nurture experimental efforts. Likewise, it can be expected that they
will also gain relevance in the biotechnological arena, replacing or
complementing the actual costly and limited experimental meth-
ods used to optimize protein solubility. In the near future, we could
expect that novel automated and more robust algorithms account-
ing from conditions extrinsic to the protein sequence and static
structure would be progressively implemented in the streamlined
workflow of companies as an easy and fast optimization step for
protein-based therapeutics; impacting both their marketing and
clinical application.
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